# CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors

> **NCT05631899** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Chinese PLA General Hospital** · enrollment: 9 (actual)

## Conditions studied

- Solid Tumor, Adult
- EphA2 Overexpression
- KRAS G12V
- KRAS G12C
- KRAS G12D

## Interventions

- **BIOLOGICAL:** KRAS-EphA-2-CAR-DC
- **DRUG:** Abraxane
- **DRUG:** Cyclophosphamide
- **DRUG:** Anti-PD-1 antibody
- **DRUG:** Anti-CTLA4 Monoclonal Antibody

## Key facts

- **NCT ID:** NCT05631899
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-04-03
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2025-11-24

## Collaborators

- Zhejiang University

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05631899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05631899, "CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05631899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*